Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Cash & Equivalents (2022 - 2025)

Corvus Pharmaceuticals has reported Cash & Equivalents over the past 4 years, most recently at $2.9 million for Q3 2025.

  • Quarterly results put Cash & Equivalents at $2.9 million for Q3 2025, down 38.74% from a year ago — trailing twelve months through Sep 2025 was $2.9 million (down 38.74% YoY), and the annual figure for FY2024 was $8.7 million, down 30.74%.
  • Cash & Equivalents for Q3 2025 was $2.9 million at Corvus Pharmaceuticals, down from $14.7 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for CRVS hit a ceiling of $31.5 million in Q1 2022 and a floor of $2.9 million in Q3 2025.
  • Median Cash & Equivalents over the past 4 years was $12.6 million (2023), compared with a mean of $13.7 million.
  • Peak annual rise in Cash & Equivalents hit 93.8% in 2024, while the deepest fall reached 76.72% in 2024.
  • Corvus Pharmaceuticals' Cash & Equivalents stood at $13.2 million in 2022, then fell by 4.1% to $12.6 million in 2023, then crashed by 30.74% to $8.7 million in 2024, then plummeted by 67.2% to $2.9 million in 2025.
  • The last three reported values for Cash & Equivalents were $2.9 million (Q3 2025), $14.7 million (Q2 2025), and $5.0 million (Q1 2025) per Business Quant data.